Home > Boards > US OTC > Biotechs > Revance Therapeutics, Inc. (RVNC)

Immediately after the delay, I never would have

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
LongRun8 Member Profile
 
Followed By 8
Posts 438
Boards Moderated 0
Alias Born 08/02/12
160x600 placeholder
Revance to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021 Business Wire - 7/29/2021 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/6/2021 4:34:46 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2021 7:56:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2021 7:54:34 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2021 7:52:54 PM
Revance to Participate in Upcoming Virtual Healthcare Conferences Business Wire - 5/26/2021 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/26/2021 8:04:50 AM
Revance Provides Update on DaxibotulinumtoxinA for Injection Pre-Approval Inspection Business Wire - 5/26/2021 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/10/2021 4:42:24 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/10/2021 4:11:10 PM
Revance Therapeutics EPS beats by $0.11, beats on revenue Seeking Alpha - 5/10/2021 4:10:14 PM
Revance Reports First Quarter 2021 Financial Results, Provides Corporate Update Business Wire - 5/10/2021 4:05:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/7/2021 7:15:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/7/2021 7:13:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/7/2021 7:11:22 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/7/2021 7:09:36 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/7/2021 7:07:11 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/7/2021 7:04:54 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2021 4:07:04 PM
Revance to Release First Quarter 2021 Financial Results on Monday, May 10, 2021 Business Wire - 5/3/2021 8:00:00 AM
Revance to Showcase Clinical Findings at The Aesthetic Meeting 2021 that Supports DaxibotulinumtoxinA’s 24-Week Long Durati... Business Wire - 4/27/2021 4:05:00 PM
Enrollment underway in Revance Therapeutics' late-stage DaxibotulinumtoxinA study Seeking Alpha - 4/27/2021 8:35:27 AM
Revance Announces First Patient Enrolled for DaxibotulinumtoxinA in Glabellar Lines & Cervical Dystonia in China by Fosun Pha... Business Wire - 4/27/2021 8:00:00 AM
Revance to Present Data on DaxibotulinumtoxinA for Injection & Hyaluronic Acid Fillers at American Academy of Dermatology VMX... Business Wire - 4/23/2021 8:00:00 AM
Revance signs supply agreement with contract manufacturer Lyophilization Seeking Alpha - 4/12/2021 4:32:25 PM
LongRun8   Friday, 05/07/21 08:47:16 PM
Re: rwwine post# 1892
Post # of 2011 
Immediately after the delay, I never would have expected the approval to come later than Labor Day 2021. Crazy that the FDA seemingly didn't travel AT ALL in 2020. I can't believe this could literally spill over into 2022. ABBV must be loving this...

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences